Article Text

other Versions

PDF
Hyaluronan synthase 2 is an adverse prognostic marker in androgen receptor-negative breast cancer
  1. Hong Zhang1,
  2. Julia Y S Tsang2,
  3. Yun-Bi Ni2,
  4. Siu-Ki Chan3,
  5. Kui-Fat Chan4,
  6. Sai-Yin Cheung4,
  7. Gary M Tse1
  1. 1Department of Pathology, Peking University First Hospital, Beijing, China
  2. 2Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
  3. 3Department of Pathology, Kwong Wah Hospital, Hong Kong, Hong Kong
  4. 4Department of Pathology, Tuen Mun Hospital, Hong Kong, Hong Kong
  1. Correspondence to Dr Gary M Tse, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Ngan Shing Street, Shatin, NT, Hong Kong; garytse{at}cuhk.edu.hk

Abstract

Aims The important role of hyaluronan synthase 2 (HAS2), an isozyme responsible for hyaluronan synthesis, in cancer has been increasingly recognised. However, only a few studies with inconsistent results have been reported in breast cancers. With a large cohort, we aim to determine the clinical significance of HAS2 in breast cancers.

Methods We examined HAS2 expression in 1142 breast cancers using immunohistochemistry.

Results HAS2 was associated with both prognostically favourable (androgen receptor (AR), p<0.001) and unfavourable (basal and epithelial mesenchymal transition markers, p≤0.039) biomarkers. In addition, HAS2 showed differential associations with various features and outcome between AR+ and AR− subgroups. HAS2+AR− breast cancers showed significantly worse outcome than other subgroups, and HAS2+AR− subgroup was an independent adverse prognostic factor for disease-free survival (HR 1.309, p=0.046). Interestingly, HAS2 was associated with many poor prognostic features (including higher grade, lymphovascular invasion, basal-like breast cancer subtype, high Ki67 and basal marker expression) only in AR−, but not AR+ breast cancers.

Conclusions HAS2 has been proposed to be a target for therapeutic intervention in cancer. Our findings suggested a possible antagonistic role of AR pathway on HAS2 function. It will be interesting to further investigate their precise interaction, which may have important implication in HAS2 targeting.

  • BREAST CANCER
  • IMMUNOCYTOCHEMISTRY
  • STAINING

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.